Evidence map›Paper›PMID 34593624›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition.

Xiaolei Liu, Anurag Verma, Gustavo Garcia, Holly Ramage, Anastasia Lucas, Rebecca L Myers, Jacob J Michaelson, William Coryell, Arvind Kumar, Alexander W Charney and 9 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.

  1. Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Lithium: current state of the art and future directions.International journal of bipolar disorders · 2024
    Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Xiaolei LiuDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-3771-4165
Anurag VermaDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Gustavo GarciaDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.ORCID 0000-0002-1649-9251
Holly RamageDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Anastasia LucasDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Rebecca L MyersPharmacology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Jacob J MichaelsonDepartment of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA 52242.
William CoryellDepartment of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA 52242.
Arvind KumarDepartment of Genetics and Genomic Sciences, Friedman Brain Institute, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-2865-1732
Alexander W CharneyDepartment of Psychiatry, Friedman Brain Institute, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Marcelo G KazanietzDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Daniel J RaderDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-9245-9876
Marylyn D RitchieDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Wade H BerrettiniCenter for Neurobiology and Behavior, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
David C SchultzDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-7890-8815
Sara CherryDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Robert DamoiseauxDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.ORCID 0000-0002-6872-5118
Peter S KleinDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; pklein@pennmedicine.upenn.edu.ORCID 0000-0002-2011-8538
University of Pennsylvania · USAllen Institute for Brain Science · USUniversity of California, Los Angeles · USUniversity of Iowa · USCalifornia NanoSystems Institute · USTranslational Therapeutics (United States) · US

Funding

HEMATOPOIESIS TRAINING GRANTT32DK007780 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI TONG, WEI · 1999 to 2023
$6.7M
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Defining the functional interface between the ER and flavivirusesR01AI140539 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHERRY, SARA, DIAMOND, MICHAEL S · 2018 to 2022
$3.0M
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Maintenance and expansion of long-term hematopoietic stem cellsR01HL141759 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S · 2018 to 2021
$2.2M
Defining the role of microbiota-derived cyclic dinucleotides in priming antiviral immune defenses.R01AI152362 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHERRY, SARA · 2020 to 2024
$2.0M
An unexpected signaling output for the tumor suppressor APCR01GM115517 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S · 2016 to 2019
$1.3M
Targeting Coronavirus through Nucleocapsid PhosphorylationR21AI161678 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S · 2021 to 2021
$447k
NEI NIH HHS R01 EY032149NHLBI NIH HHS R01 HL141759NIAID NIH HHS R01 AI140539NIAID NIH HHS R01 AI152362NIAID NIH HHS R21 AI161678NIDDK NIH HHS R01 DK132735NIDDK NIH HHS T32 DK007780NIGMS NIH HHS R01 GM115517NIH HHS 1R01 AI1502461NIH HHS 1R01 EY032149NIH HHS 1R01 GM115517NIH HHS 1R01 HL141759NIH HHS 5R01 AI140539Wellcome Trust
6 · The paper itself

Abstract

The coronaviruses responsible for severe acute respiratory syndrome (SARS-CoV), COVID-19 (SARS-CoV-2), Middle East respiratory syndrome-CoV, and other coronavirus infections express a nucleocapsid protein (N) that is essential for viral replication, transcription, and virion assembly. Phosphorylation of N from SARS-CoV by glycogen synthase kinase 3 (GSK-3) is required for its function and inhibition of GSK-3 with lithium impairs N phosphorylation, viral transcription, and replication. Here we report that the SARS-CoV-2 N protein contains GSK-3 consensus sequences and that this motif is conserved in diverse coronaviruses, raising the possibility that SARS-CoV-2 may be sensitive to GSK-3 inhibitors, including lithium. We conducted a retrospective analysis of lithium use in patients from three major health systems who were PCR-tested for SARS-CoV-2. We found that patients taking lithium have a significantly reduced risk of COVID-19 (odds ratio = 0.51 [0.35-0.74],

Indexed as

AdultAgedCoronavirus Nucleocapsid ProteinsCOVID-19FemaleGlycogen Synthase Kinase 3HEK293 CellsHumansLithium CompoundsMaleMiddle AgedMolecular Targeted TherapyPhosphoproteinsPhosphorylationRetrospective StudiesCoronavirus Nucleocapsid ProteinsGlycogen Synthase Kinase 3Lithium Compoundsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinscoronavirusCOVID19GSK-3lithiumnucleocapsid

Identifiers

PMID34593624
PMCPMC8594528
OpenAlexW3203702046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.